I don't know why the funding question keeps arising. Dr. Missling has never misled us yet to my knowledge. He has a very strong Board of Directors that I would assume would not jeopardise their reputations by allowing him to mislead.
Perhaps by different ones bringing this question up is just a little FUD or soft bashing.
Here are some points presented numerous times on this board regarding funding.
From The Wall Street Transcripts interview :
Dr. Missling's answer to funding.
TWST: Do you have the financing you need to get through the development of ANAVEX 2-73 at this current stage?
Dr. Missling: Yes, we believe that sufficient financing in place and also because we are working with several foundations on specific diseases like the Michael J. Fox Foundation that has supported us very strongly for exploring ANAVEX 2-73 in a pre-clinical study of Parkinson’s disease, for which positive data was recently reported on September 22nd. And we also received support from the Rettsyndrome.org foundation, which also supported exploring ANAVEX 2-73 in a pre-clinical study in Rett syndrome, a rare disease for which Anavex received FDA orphan designation this year. We might continue these collaborations if the data continues to be promising.
Filed with SEC 10/21/16 This is superb Media coverage,
The Wall Street Transcript is a completely unique resource for investors and business researchers.
Over 20,000 CEO, Equity Analyst and Money Managers
Filed with the SEC.
EX-99.1 2 s104371_ex99-1.htm EXHIBIT 99-1
Exhibit 99.1
Christopher U. Missling, MS, PhD, MBA, President and CEO of Anavex Life Sciences Corp.
Australia information:
Funding? MacFarlane does the research at Caufield Hospital a unit of the Alfred Group in Australia. Here are some excerpts from Alfred Group's Annual Report 2015-16 published August 2016. This indicates that a great deal of funding comes from partnerships.
(Page 4 - Alfred Group annual Report 2015-16)
Chairperson and Chief Executive’s Year in Review (continued)
Discovering the next generation of care Partnerships continued to underpin significant research developments that informed clinical practice in Australia and overseas. Researchers from The Alfred answered the long-held debate over whether aspirin should be stopped before coronary artery surgery. The results of the 10-year international study showed no increased risk of surgical bleeding or need for blood transfusion associated with asprin use. Scientists from The Alfred and Monash University made a breakthrough in targeting aggressive blood cancers through combination therapy, giving hope to people suffering from Acute Myeloid Leukaemia. At our Caulfield campus, early research results from the international drug trial of Anavex 2-73, which aims to address the symptoms of dementia, were positive. Also significant was the announcement of PrEPX, a new public health research study supported by Alfred Health, the Victorian Government and the Victorian AIDS Council. This study will expand access to pre-exposure prophylaxis (‘PrEP’) medication to prevent HIV infection in people who are at high risk.
(Page 26 )
Research through partnership
This year’s achievements included care to prevent HIV infection, hope for those suffering severe asthma and dementia and a breakthrough in fighting blood cancer. We continued to attract a high level of funding from the National Health and Medical Research Council.
(Page 27)
Alzheimer’s drug trial success
Early research results of Anavex 2-73, a drug which aims to address the symptoms of dementia, are positive. Trials at Caulfield Hospital are using Anavex, which, unlike current medications, is the only drug designed to both relieve symptoms and slow the disease’s progression. The first phase of the trial began in December 2014 and the next steps will involve further research with a larger group of participants in 2017.
